Vivo Bio Tech Quarterly Results for Trading Insights
In Mar 2026, Vivo Bio Tech (VIVOBIOT) reported revenue ₹14 Cr and net profit ₹-5 Cr — revenue +16.7% YoY. Browse VIVOBIOT annual financials for revenue, profit, balance sheet and cash flow data.
VIVOBIOT Quarterly Results — Revenue, Profit & EPS Highlights
Vivo Bio Tech latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore VIVOBIOT share price data to track price trends across different timeframes.
- Revenue of ₹14 Cr in Mar 2026 (+7.7% vs Sept 2025, +16.7% vs Mar 2025)
- Net Profit of ₹-5 Cr in Mar 2026 (-600.0% vs Sept 2025, -600.0% vs Mar 2025)
- EBITDA of ₹5 Cr in Mar 2026 (-16.7% vs Sept 2025)
- Operating Margin of 31.0% in Mar 2026 (-10.0pp vs Sept 2025)
- Earnings Per Share of ₹-2.52 in Mar 2026 (-660.0% vs Sept 2025)
Vivo Bio Tech Quarterly Results — Revenue, EBITDA, Net Profit & EPS
VIVOBIOT quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 14 | 13 | 12 | 13 | 14 | 7.7% | 16.7% |
| Net Profit (₹ Cr) | -5 | 1 | 1 | 1 | 1 | - | - |
| EBITDA (₹ Cr) | 5 | 6 | 5 | 6 | 6 | - | - |
| EPS (₹) | -2.52 | 0.45 | 0.69 | 0.74 | 0.56 | - | - |
| Operating Margin (%) | 31.0% | 41.0% | 41.0% | 44.0% | 41.0% | - | - |
VIVOBIOT Share Price Trend — 1-Year Movement Across Quarterly Results
Vivo Bio Tech 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Vivo Bio Tech share price chart.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
VIVOBIOT vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Vivo Bio Tech latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹457,721.13 Cr | 1912.8 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 169.3 |
|
Divis Laboratories
Mar 2026 |
₹174,081.02 Cr | 6857.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 242.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹161,380.94 Cr | 4822.7 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 419.0 |
|
Cipla
Mar 2026 |
₹117,800.00 Cr | 1472.3 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 214.3 |
|
Zydus Life Science
Mar 2026 |
₹115,505.60 Cr | 1147.9 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 90.7 |
All amounts in ₹ Crores